Zoek een klinische studie of trial
Andere zoekoptie(s)
9 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Terminated trial
= 
; Gefinancierd door een IRDiRC-lid = 
; Lid van een ERN = 
Nationale klinische studie(s)
BELGIË
VLAAMS BRABANT
LEUVEN
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older With an Extension Period of Up To 60 Months - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older With an Extension Period of Up To 60 Months - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks - AT
Institution: Information not provided - AT
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older With an Extension Period of Up To 60 Months -ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2, Single-arm, Pathologist-blinded Study Using Liver Biopsy Specimens to Assess Copper Concentration and Histopathologic Changes in Patients With Wilson Disease Who Are Treated With ALXN1840 for 48 Weeks Followed by an Extension Treatment Period With ALXN1840 for up to an Additional 48 Weeks -ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease -ES
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Disease - ES
Institution: Information not provided - ES
USA
Connecticut
CHESHIRE
A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840
Alexion Pharmaceuticals, Inc.
Multinationale klinische studie(s)
USA
Connecticut
CHESHIRE